Bioluminescence imaging allows monitoring hepatitis C virus core protein inhibitors in mice

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Du, Juan ^a   Zhao, Fang ^a   Zhou, Yong ^a   Yan, Hu ^a   Duan, Xiang Guo ^b   Liang, Sheng Qiang ^a   Wang, Ying Li ^a   Fu, Qiu Xia ^a   Wang, Xiao Hui ^a   Peng, Jian Chun ^a   Zhan, Lin Sheng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORE PROTEIN; LUCIFERASE; SHORT HAIRPIN RNA; SHORT HAIRPIN RNA 452; SHORT HAIRPIN RNA 523; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS RNA; ALANINE AMINOTRANSFERASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BIOLUMINESCENCE; DRUG MONITORING; DRUG SCREENING; DRUG TARGETING; HEPATITIS C VIRUS; IN VIVO STUDY; LIVER; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; ANIMAL; BLOOD; C57BL MOUSE; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; LUMINESCENCE; METABOLISM; METHODOLOGY; REPRODUCIBILITY; RNA INTERFERENCE; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALIA; HEPATITIS C VIRUS; MUS;

ALANINE TRANSAMINASE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIVER; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED C57BL; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; VIRAL CORE PROTEINS;

EID: 78649508228     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014043     Document Type: Article

References (35)

1. Lauer GM, Walker BD (2001) Hepatitis C virus infection. The New England journal of medicine 345: 41-52.
2. Choo QL, Kuo G, Weiner AJ (1989) Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 244: 359-362.
3. Bukh J, Purcell RH, Miller RH (1994) Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 91: 8239-8243.
4. McLauchlan J (2000) Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 7: 2-14.
5. Liu Q, Tackney C, Bhat RA, Prince AM, Zhang, P (1997) Regulated processing of hepatitis C virus core protein is linked to subcellular localization. J Virol 71: 657-662.
6. Santolini E, Migliaccio G, La Monica N (1994) Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol 68: 3631-3641.
7. Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi SI, Ichikawa M, et al. (1998) The native form and maturation process of hepatitis C virus core protein. J Virol 72: 6048-6055.
8. Ray RB, Meyer K, Ray R (2000) Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 271: 197-204.
9. Sacco R, Tsutsumi T, Suzuki R, Otsuka M, Aizaki H, et al. (2003) Antiapoptotic regulation by hepatitis C virus core protein through up-regulation of inhibitor of caspase-activated DNase. Virology 317: 24-35.
10. Siavoshian S, Abraham JD, Thumann C, Kieny MP, Schuster C (2005) Hepatitis C virus core, NS3, NS5A, NS5B proteins induce apoptosis in mature dendritic cells. J Med Virol 75: 402-411.
11. Ishikawa T, Shibuya K, Yasui K, Mitamura K, Ueda S (2003) Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. Comp Immuno Microbiol Infec Dis 26: 115-124.
12. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, et al. (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78: 1527-1531.
13. Groth AC, Olivares EC, Thyagarajan B, Calos MP (2000) A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci USA 97: 5995-6000.
14. Zhao F, Liang SQ, Zhou Y, Wang YL, Yan H, et al. (2010) Evaluation of hepatitis B virus promoters for sustained transgene expression in mice by bioluminescence imaging. Virus Res 149: 162-166.
15. Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B (2002) Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 296: 2215-2218.
16. Suzuki H, Tamai N, Habu Y, Chang MOO, Takaku H (2008) Suppression of hepatitis C virus replication by baculovirus vector-mediated short-hairpin RNA expression. FEBS Letters 582: 3085-3089.
17. Suzuki H, Kaneko H, Tamai N, Shimotohno K, Naoko MK, et al. (2007) Suppression of hepatitis C virus core protein by short hairpin RNA expression vectors in the core protein expression Huh-7 cells. Nucleosides Nucleotides and Nucleic Acids 26: 815-820.
18. Kim M, Shin D, Kim SI, Park M (2006) Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus Res 122: 1-10.
19. Liu F, Song YK, Liu D (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene ther 6: 1258-1266.
20. Lecocq M, Andrianaivo F, Warnier MT, Coninck SW, Wattiaux R, et al. (2003) Uptake by mouse liver and intracellular fate of plasmid DNA after a rapid tail vein injection of a small or a large volume. J Gene Med 5: 142-156.
21. Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, et al. (2002) Sitespecific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol 20: 1124-1128.
22. Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP (2001) Sitespecific genomic integration in mammalian cells mediated by phage QC31 integrase. Mol Cell Biol 21: 3926-3934.
23. Ortiz-Urda S, Thayagarajan B, Keene DR, Lin Q, Fang M, et al. (2002) Stable nonviral genetic correction of inherited human skin disease. Nat Med 8: 1166-1170.
24. Bertoni C, Jarrahian S, Wheeler TM, Li Y, Olivares EC, et al. (2006) Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc Natl Acad Sci USA 103: 419-424.
25. Budker VG, Subbotin VM, Budker T, Sebestyen MG, Zhang GF, et al. (2006) Mechanism of plasmid delivery by hydrodynamic tail vein injection. II. Morphological studies. J Gene Med 8: 874-888.
26. Kronke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, et al. (2004) Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J virol 78: 3436-3446.
27. Kapadia SB, Brideau-Andersen A, Chisari FV (2003) Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 100: 2014-2018.
28. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, et al. (2003) Inhibition of intracellular hepatitis C virus replication by synthetic and vectorderived small interfering RNAs. EMBO Rep 4: 602-608.
29. Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue IG, et al. (2003) RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci USA 100: 2783-2788.
30. Held PK, Olivares EC, Aguilar CP, Finegold M, Calos MP, et al. (2005) In vivo correction of murine hereditary tyrosinemia type I by WC31 integrase-mediated gene delivery. Mol Ther 11: 399-408.
31. Keravala A, Lee S, Thyagarajan B, Olivares EC, Gabrovsky VE, et al.(2009) Mutational derivatives of phiC31 integrase with increased efficiency and specificity. Mol Ther 17: 112-120.
32. Aneja MK, Imker R, Rudolph C (2007) Phage phiC31 integrase-mediated genomic integration and long-term gene expression in the lung after nonviral gene delivery. J Gene Med 9: 967-975.
33. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, et al. (2005) Sequencedependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23(4): 457-462.
34. Sioud M (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348(5): 1079-1090.
35. Lewis DL, Wolff JA (2005) Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Methods Enzymol 392: 336-350.